We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Please provide feedback for this on the following(scale 1-5, 1 strongly disagree; 5 strongly agree):
* = Mandatory Field
BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions that remain to be answered, are discussed in this touchHAEMATOLOGY interview with Dr Mark Levis (Sidney […]
We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts discussed: Abstract S130: ‘Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing […]
The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), one of our valued Editorial Board members, to discuss the latest durability of response and safety results […]
Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the current therapeutic options for myelofibrosis and their limitations. The abstract entitled ‘UPDATED DURABILITY […]
President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023. Questions: Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18) […]
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the main findings of the REVIVE study and the […]
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, rationale and methodology of the REVIVE study are discussed in this touchHAEMATOLOGY interview with Dr […]
In this interview, touchHAEMATOLOGY are joined by Professor Per Ljungman (Karolinska University Hospital, Stockholm, Sweden) to discuss the updated results of the EBMT COVID-19 Task Force study exploring study exploring the outcomes and mortality in cytomegalovirus seropositive allogeneic stem cell transplantation patients with COVID-19. Questions 1. Please describe the rationale and main aims of your […]
Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), summarizes the main take-home messages from her educational session on the latest improvements in autologous stem cell transplantation for patients with Hodgkin lymphoma. These include the introduction of new drugs in the salvage setting such as checkpoint inhibitors, improvements to long-term […]
Get the latest clinical insights from touchHAEMATOLOGY